These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25364229)

  • 1. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
    Jekunen A
    Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
    Betz UA
    Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future pharmaceutical research: the need to look beyond science.
    Seeger S
    Future Med Chem; 2014 May; 6(7):721-3. PubMed ID: 24941866
    [No Abstract]   [Full Text] [Related]  

  • 4. An unbalanced portfolio.
    Federsel HJ
    Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portfolio analysis and R&D decision making.
    Evans R; Hinds S; Hammock D
    Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
    [No Abstract]   [Full Text] [Related]  

  • 6. Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures.
    Bieske L; Zinner M; Dahlhausen F; Trübel H
    Drug Discov Today; 2023 Oct; 28(10):103734. PubMed ID: 37572999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective executive management in the pharmaceutical industry.
    Tran H; Kleiner BH
    J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Going beyond probability of success: Opportunities for statisticians to influence quantitative decision-making at the portfolio level.
    Wiklund SJ; Thorn K; Götte H; Hacquoil K; Saint-Hilary G; Carlton A;
    Pharm Stat; 2024; 23(3):429-438. PubMed ID: 38212898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
    Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.
    Donelan R; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):319-28. PubMed ID: 25628072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic biopharmaceutical portfolio development: an analysis of constraint-induced implications.
    George ED; Farid SS
    Biotechnol Prog; 2008; 24(3):698-713. PubMed ID: 18426243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent portfolio management: literature review and a proposed model.
    Conegundes De Jesus CK; Salerno MS
    Expert Opin Ther Pat; 2018 Jun; 28(6):505-516. PubMed ID: 29718747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical research and development and the patent system.
    Love J
    Int J Health Serv; 2005; 35(2):257-63. PubMed ID: 15932006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical utility index as a practical multiattribute approach to drug development decisions.
    Poland B; Hodge FL; Khan A; Clemen RT; Wagner JA; Dykstra K; Krishna R
    Clin Pharmacol Ther; 2009 Jul; 86(1):105-8. PubMed ID: 19458614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.